Clinical trials: Hair Condition
Alopecia Areata, Alopecia Totalis
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03551821
- Testing
- ATI-50002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Alopecia Areata
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
- Trial name
- NCT02553330
- Testing
- Ruxolitinib Phosphate Cream
- Where
- 18 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
This first in human phase 1 study to Study will evaluate safety, tolerability, and pharmacokinetics of Single Ascending dose (SAD), Food effect (FE) and Multiple ascending dose (MAD) of OR-101 Administered Orally in healthy…
- Trial name
- NCT06045624
- Testing
- OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose)
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ornovi, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451125
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Hair Loss
Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women.
- Trial name
- NCT07556016
- Testing
- Active nutricosmetic
- Where
- 4 sites in France
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety…
- Trial name
- NCT07076706
- Testing
- minoxidil + finasteride
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Alopecia
Treatment of Androgenetic Alopecia in Men for 24 Weeks
A prospective, randomized, double-blind, single-center, placebo-Controlled, parallel-group study to evaluate the efficacy and safety of a new pharmaceutical form Minoxidil 5% in men after 24 weeks of treatment.
- Trial name
- MINOX (NCT04721548)
- Testing
- Minoxidil Topical Foam
- Where
- Brazil
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Hirsutism, Hypertrichosis
Enhanced Safety Aesthetic Laser System
The purpose of this study is to determine whether a new laser system provides better safety and efficacy than existing lasers in popular cosmetic procedures such as hair removal, treatment of cosmetically disturbing vascular…
- Conditions
- Hirsutism, Hypertrichosis, Telangiectases, Rhytides
- Trial name
- NCT00495443
- Testing
- Peterio
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Scilex Ltd.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)
To evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451047
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 7 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial
The goal of this clinical trial is to compare 3 different types of PRP in androgenetic alopecia patients. The main questions it aims to answer: Does Redlight enhanced, Blue light enhanced, or traditional PRP result in higher hair…
- Trial name
- NCT07739147
- Testing
- Platelet-Rich Plasma (PRP) Injections, Red-light photobiomodulation with cooling, Blue-light photobiomodulation
- Volunteers
- 30 people
- Sponsor
- Kimberly Meathrel
Sensorineural Hearing Loss, Tinnitus
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss.
- Conditions
- Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury
- Trial name
- HEAR-RESTORE (NCT07472023)
- Testing
- Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Alopecia Areata
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur.
- Trial name
- NCT07533006
- Testing
- LY4005130
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata.
- Trial name
- NCT05041803
- Testing
- CTP-543
- Where
- 39 sites in France, Germany and 3 more
- Volunteers
- 407 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AAJP (NCT07617597)
- Testing
- Deuruxolitinib
- Where
- 18 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Sun Pharma Japan Limited
Facial Aging, Rejuvenation
Secretome Treatment for Facial Rejuvenation
Secretome treatment for facial rejuvenation
- Conditions
- Facial Aging, Rejuvenation, Stem Cell, Stem Cell Banking
- Trial name
- NCT07227883
- Testing
- Autologous Hair Follicle-Derived Secretome, Control Saline
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Acorn Biolabs Inc.
Menkes Disease, Occipital Horn Syndrome
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Menkes disease and occipital horn syndrome are two forms of copper deficiency that must be diagnosed and treated very early in life to prevent serious developmental problems.
- Conditions
- Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency
- Trial name
- NCT00811785
- Testing
- Copper Histidine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Cyprium Therapeutics, Inc.
Alopecia Areata
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
This clinical trial attempts to investigate the efficacy of LEO 124249 ointment in the treatment of alopecia areata on the eyebrows.
- Trial name
- NCT03325296
- Testing
- LEO 124249, Ointment vehicle
- Where
- 2 sites in Denmark
- Volunteers
- 13 people
- Sponsor
- LEO Pharma